药理学博士，中医药健康学院专任教师。从事中药及化学合成药物抗肿瘤、抗骨质疏松和抗病毒的活性与机制研究。博士毕业于南方医科大学药学院，荣获博士一等学业奖学金、中国药理学会抗炎免疫药理委员会青年优秀论文三等奖、广东省药理学会青年优秀论文三等奖。主持国家自然青年科学基金项目1项、参与省部及以上项目两项。近五年公开发表学术论文11篇，其中以第一作者发表SCI论文6篇，中科院小类1区5篇，中文核心论文3篇，申请发明专利1项。

研究

从事中药及化学合成药物抗肿瘤、抗骨质疏松和抗病毒的活性与机制研究。

出版物

1. Integration of network pharmacology with experimental validation to reveal the mechanism of action of Longdan Xiegan Decoction against HSV2 infection and determine its effective components. J Ethnopharmacol. 2024 May: 325:117861.（小类1区，IF: 5.4）一作

2. Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome. Biomed Pharmacother. 2022 Dec: 156:113946.（小类1区，IF: 7.419）一作

3. A011, a novel small-molecule ligand of σ2 receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy. Biomed Pharmacother. 2022 Aug:152:113232.（小类1区，IF: 7.419）一作

4. Prediction of the mechanisms of Xiaoai Jiedu Recipe in the treatment of breast cancer: A comprehensive approach study with experimental validation. J Ethnopharmacol. 2020 Apr 24:252:112603（小类1区，IF: 5.4 ）一作

5. Network pharmacology combined with bioinformatics to investigate the mechanism of Xianlinggubao capsule in the treatment of osteoporosis. Phytomedicine Plus. 2021 1(3):100049. 一作

6. Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ(2)R /TMEM97 ligands. Eur J Med Chem. 2021 Jan 1:209:112906.（大类1区、IF: 7.08）共一第二

7. Predicting and Exploring the Mechanisms of Erzhi Pill in Prevention and Treatment of Osteoporosis Based on Network Pharmacology and Zebrafish Experiments. DrugDes Devel Ther. 2021 Feb 24:15:817-827. （小类2区，IF: 4.8）共一第二

8. 四氢异喹啉类新化合物SYT-1抑制肿瘤细胞增殖的机制。药学学报. 2021; 56(01): 217-23. （北大核心）一作

9. 基于网络药理学探讨丹参治疗骨质疏松症的作用机制。中医学报. 2020; 35(04): 853-8. （科技核心）一作

专利

2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用、ZL201911189046.1，发明专利、排名第三